7XE.F NIGHTINGALE HEALTH EO 1
- Market cap
- EUR 112M
- P/E
- -
- P/B
- 2.55x
- ROE
- -37.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 7XE.F undervalued?
Graham numberThe Graham number of NIGHTINGALE HEALTH EO 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NIGHTINGALE HEALTH EO 1 fundamental analysis
No fundamental analysis for NIGHTINGALE HEALTH EO 1 yet.
NIGHTINGALE HEALTH EO 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NIGHTINGALE HEALTH EO 1
Nightingale Health Oyj, a health technology company, offers advanced health check that detects disease risks in Finland, Europe, the Middle East, Africa, AMER, and the Asia-Pacific. The company's Health Check that detects the risks associated with various common chronic diseases from a single blood sample; and Remote Health Check where health check done remotely, as well as multiomics analysis services. It provides its services to research programs, universities, and healthc…
Full company profileNIGHTINGALE HEALTH EO 1 financial statements
NIGHTINGALE HEALTH EO 1 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.31M | 4.18M | 4.36M | 4.69M | 5.50M |
| Gross Profit | 1.28M | 3.59M | 2.90M | 3.54M | 2.84M |
| Operating Income | -13.7M | -18.7M | -18.6M | -19.4M | -18.8M |
| EBITDA | - | -11.4M | -8.42M | -10.1M | -11.6M |
| Net Income | -16.1M | -18.1M | -17.5M | -18.5M | -18.5M |
| EPS | -0.27 | -0.30 | -0.29 | -0.31 | -0.31 |
| Balance Sheet | |||||
| Total Assets | 124M | 107M | 90.8M | 74.5M | 58.1M |
| Total Liabilities | 12.6M | 9.44M | 7.96M | 8.35M | 9.32M |
| Shareholders' Equity | 111M | 97.4M | 82.9M | 66.2M | 48.7M |
| Cash & Short-term Investments | 95.3M | 80.6M | 43.7M | 41.3M | 36.8M |
| Cash Flow | |||||
| Operating Cash Flow | -7.47M | -7.33M | -8.41M | -10.1M | -10.9M |
| Capital Expenditure | 7.61M | 4.41M | 4.59M | 4.15M | 2.22M |
| Free Cash Flow | -15.1M | -11.7M | -13.0M | -14.3M | -13.1M |
| Ratios | |||||
| ROE | -14.4% | -18.6% | -21.1% | -27.9% | -37.9% |
| ROA | -13.0% | -16.9% | -19.2% | -24.8% | -31.8% |
| Net Profit Margin | -695.7% | -432.4% | -400.7% | -393.4% | -335.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NIGHTINGALE HEALTH EO 1 dividends
NIGHTINGALE HEALTH EO 1 has not paid dividends in the last 5 fiscal years.
Who owns NIGHTINGALE HEALTH EO 1
- Insiders 33.57%
- Institutions 7.32%
- Public & others 59.12%
- Shares outstanding 40.6M
- Free float 29.8M
NIGHTINGALE HEALTH EO 1 company profile
- Company name
- NIGHTINGALE HEALTH EO 1
- Ticker
- 7XE.F
- ISIN
- FI4000490875
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 101
- Fiscal year end
- June
- Address
- Mannerheimintie 164a, Helsinki, Finland, 00300
- Phone
- 358 207301810
- Website
- nightingalehealth.com
About NIGHTINGALE HEALTH EO 1
Nightingale Health Oyj, a health technology company, offers advanced health check that detects disease risks in Finland, Europe, the Middle East, Africa, AMER, and the Asia-Pacific. The company's Health Check that detects the risks associated with various common chronic diseases from a single blood sample; and Remote Health Check where health check done remotely, as well as multiomics analysis services. It provides its services to research programs, universities, and healthcare providers. The company has a collaboration with Personalised Health Clinics to incorporate the company's metabolomic blood testing into Personalised Health Clinics' personalized, clinician-led healthcare services. Nightingale Health Oyj was incorporated in 2002 and is based in Helsinki, Finland.
NIGHTINGALE HEALTH EO 1 management
10- Mr. Teemu SunaFounder, Interim CFO, CEO & Director · born 1982
- Mr. Antti KangasFounder, CTO & Director · born 1984
- Ms. Satu SaksmanCo-Founder & Chief Commercial Officer of APAC · born 1976
- Mr. Peter Wurtz Ph.D.Founder & Scientific Director
- Mr. Pasi Soininen Ph.D.Founder & Laboratory Director
- Ms. Janna RantaCOO and Chief Commercial Officer of Research & Healthcare · born 1985
- Ms. Satu Sirén-LähdeahoGeneral Counsel
- Ms. Minja SalmioChief Commercial Officer of EMEA Region · born 1987
- Ms. Salla Ruosaari Ph.D.Chief Research & Development Officer · born 1976
- Dr. Charles AlessiChief Clinical Officer